WebMD has appointed Kavan Redmond, a former senior executive at Pfizer, as its new CEO to bolster its struggling share price. This move is criticized as a blatant conflict of interest, placing a "Big Pharma" shill in charge of a primary source for consumer health information. The company's stock has remained stagnant despite efforts to find new "sustainable growth platforms."
